[en] Sitagliptin (Januvia), the first selective inhibitor of dipeptidylpeptidase-4, has been assessed in a large Belgian prospective observational study. The aim of the SUGAR study was to evaluate the efficacy of sitagliptin, at a dose of 100 mg once daily, when it was added in patients with uncontrolled type 2 diabetes followed in real life conditions. In the intent-to-treat population (n = 605), mean glycated haemoglobin level decreased from 8.41 +/- 1.18% to 7.29 +/- 0.86% after a follow up averaging 110 days (p < 0.0001). Similarly, mean fasting plasma glucose level decreased from 180 +/- 50 mg/dl to 141 +/- 37 mg/ dl (p < 0.0001). The improvement of these two parameters was observed independently of basal demographic characteristics, but was directly influenced by baseline initial corresponding values. The vast majority of patients included in SUGAR were initially treated by metformin as monotherapy (current criterion for sitagliptin reimbursement in Belgium); metformin daily dose slightly decreased when sitagliptin was added (from 1975 +/- 681 mg to 1919 +/- 667 mg; p = 0.033). Patients receiving other glucose-lowering agents, as single or combined therapies, had also a significant alleviation of their treatment when sitagliptin was added. After 3-6 months of follow up, more than 95% of patients still received sitagliptin, arguing for both the efficacy and the good tolerance of this new oral antidiabetic agent in clinical practice.
Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale
Van Gaal, L. F.
Language :
French
Title :
SUGAR: resultats d'une etude observationnelle belge concernant l'utilisation de la sitagliptine chez des patients diabetiques de type 2.
Alternative titles :
[en] Sugar: results of a Belgian observational study on the use of sitagliptin in patients with type 2 diabetes
Lyseng-Williamson KA. - Sitagliptin. Drugs, 2007, 67, 587-597. (Pubitemid 46440314)
Scheen AJ, Van Gaal LF. - Sitagliptine (Januvia®). Incrétinopotentiateur indiqué comme insulinosécré tago-gue dans le traitement du diabète de type 2. Rev Med Liège, 2008, 63, 105-109.
Scheen AJ. - Le glucagon-like peptide-1 (GLP-1), nou-velle cible dans le traitement du diabète de type 2. Rev Med Liège, 2007, 62, 216-219.
Nathan DM, Buse JB, Davidson MB, et al. - Medical management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia, 2009, 52, 17-30.
Scheen AJ, Radermecker R P, Philips JC, et al. - Le trai-tement du diabète de type 2: entre insulinosensibilisa-teurs et insulinosécrétagogues. Rev Med Liège, 2007, 62, 5-6, 40-46.
Scheen AJ, Paquot N. - Quelle nouvelle donne pour soi-gner les patients diabétiques de type 2 ? Médecine des Maladies Métaboliques, 2009, 3, 141-146.
Chapell R, Gould AL, Alexander CM. - Baseline differences in A1C explain apparent differences in efficacy of sitagliptin, rosiglitazone and pioglitazone. Diabetes Obes Metab, 2009, 11, 1009-1016.
Charbonnel B, Karasik A, Liu J, et al. - Efficacy and safety of the dipeptidyl peptidase-4 inhibitor siatglip-tin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care, 2006, 29, 2638-2643. (Pubitemid 44912191)
Nauck M, Meiniger G, Sheng D, et al. - Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metfor-min alone: a randomized, double-blind, non-inferiority trial. Diab Obes Metab, 2007, 9, 194-205.
Scott R, Loeys T, Davies MJ, et al. - Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab, 2008, 10, 959-969.
Hermansen K, Kipnes M, Luo E, et al. - Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diab Obes Metab, 2007, 9, 733-745. (Pubitemid 47261855)
Rosenstock J, Brazg R, Andryuk PJ, et al. - Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sita-gliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo controlled, parallel-group study. Clin Ther, 2006, 28, 1556-1568. (Pubitemid 44841980)
Stratton IM, Adler AI, Neil HA, et al. - Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35) : prospective observational study. BMJ, 2000, 321, 405-412. (Pubitemid 30609442)
Drucker DJ, Nauck MA. - The incretin system: gluca-gon-like peptide-1 receptor agonists and dipeptidyl pep-tidase-4 inhibitors in type 2 diabetes. Lancet, 2006, 368, 1696-1705.
Scheen AJ, Radermecker R P, Philips JC, Paquot N. - Les incrétinomimétiques et incrétinopotentiateurs dans le traitement du diabète de type 2. Rev Med Suisse, 2007, 3, 1884-1888. (Pubitemid 47425207)
Schwarz B, Gouveia M, Chen J, et al. - Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy. Diabetes Obes Metab, 2008, 10, 43-55.
Herman GA, Bergman A, Yi B, et al. - Tolerability and pharmacokinetics of metformin and the dipeptidyl pep-tidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes. Curr Med Res Opin, 2006, 22, 1939-1947. (Pubitemid 44663399)
Scheen AJ. - Dipeptidylpeptidase-4 inhibitors (gliptins) : focus on drug-drug interactions. Clin Pharmacokinet, 2010, 49, in press.
Reynolds JK, Neumiller JJ, Campbell RK. - Janumet: a combination product suitable for use in patients with Type 2 diabetes. Expert Opin Invest Drugs, 2008, 17, 1559-1565.
Green J, Feinglos M. - New combination treatments in the management of diabetes: focus on sitagliptin-met-formin. Vasc Health Risk Manag, 2008, 4, 743-751.
Goldstein BJ, Feinglos MN, Lunceford JK, et al. - Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on gly-cemic control in patients with type 2 diabetes. Diabetes Care, 2007, 30, 1979-1987.
Schernthaner G, Barnett AH, Betteridge J, et al. - Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. Diabetologia, 2010, 53, in press.
Similar publications
Sorry the service is unavailable at the moment. Please try again later.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.